Prospective, Non-interventional, Observational Study for Multi-dimensional Assessment of Signs, Symptoms, Quality of Life and Disease Control of Long-term Treatment With Dupilumab in Patients With Atopic Dermatitis (≥6 Years)
Latest Information Update: 19 Mar 2024
Price :
$35 *
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms PROTYPE2
- Sponsors Sanofi
- 18 Sep 2023 New trial record